Description
FOXO4-DRI 10 mg (Proxofim) is a synthetic D-retro-inverso peptide engineered to disrupt the FOXO4-p53 interaction that allows senescent cells to resist apoptosis. By reinstating p53-mediated cell death in these cells, FOXO4-DRI functions as a potent senolytic agent in pre-clinical studies, opening new avenues for research into age-related degeneration and chronic inflammatory conditions.
Key Features:
-
Manufactured under stringent cGMP-like conditions to ensure ≥99 % purity and batch-to-batch consistency.
-
Lyophilized powder for maximum stability; reconstitutes rapidly in sterile distilled water or buffer.
-
Extensively validated by HPLC and mass spectrometry for precise molecular integrity.
Applications:
-
Investigating senolytic mechanisms and selective clearance of senescent cells.
-
Exploring therapeutic potential in age-associated tissue dysfunction and metabolic decline.
-
Assessing downstream effects on oxidative stress, insulin signaling, and cancer cell plasticity.
Specifications and Documentation
-
Material Safety Data Sheet (MSDS): Coming Soon.
-
Handling and Storage Instructions: Coming Soon.
FOXO4-DRI has emerged as a valuable research tool for probing cellular senescence, regenerative biology, and longevity science, offering investigators a robust platform for advancing anti-aging and disease-modifying strategies.
There are no reviews yet.